Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than a decade at the helm, Gibson stepped down as CEO in November 2025. And his ...
Back in 2017, the Department of Defense launched Project Maven -- an initiative to improve intelligence data from sensors, satellites, drones, and radar, and mine it for more usable insights. The ...
Early in the Covid-19 pandemic, the governor of New Jersey made an unusual admission: He’d run out of COBOL developers. The state’s unemployment insurance systems were written in the 60-year-old ...
In the era of A.I. agents, many Silicon Valley programmers are now barely programming. Instead, what they’re doing is deeply, deeply weird. Credit...Illustration by Pablo Delcan and Danielle Del Plato ...
After securing another major partnership, Factorial is closing in on bringing its “groundbreaking” all-solid-state EV battery platform to global markets. Factorial’s solid-state battery cells are ...
Karma Kaveya ultra-luxury super-coupe EV (Source: Karma Automotive) Solid-state EV batteries, deemed the “holy grail” of battery tech, are moving from the lab to reality, even in the US. Factorial ...
When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results